Mtb32 is a promising tuberculosis antigen for DNA vaccination in pre- and post-exposure mouse models (Q45873661)

17 December 2017

title

Mtb32 is a promising tuberculosis antigen for DNA vaccination in pre- and post-exposure mouse models (English)

1 reference

17 December 2017

1 reference

S-S Ahn

1

1 reference

17 December 2017

B-Y Jeon

2

1 reference

17 December 2017

K-S Kim

3

1 reference

17 December 2017

J-Y Kwack

4

1 reference

17 December 2017

E-G Lee

5

1 reference

17 December 2017

K-S Park

6

1 reference

17 December 2017

Y-C Sung

7

1 reference

17 December 2017

S-N Cho

8

1 reference

17 December 2017

publication date

29 September 2011

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

19

1 reference

17 December 2017

issue

5

1 reference

17 December 2017

page(s)

570-575

1 reference

17 December 2017

Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature

cites work

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Variation in protection by BCG: implications of and for heterologous immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

TB subunit vaccines--putting the pieces together

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

DNA vaccines for therapy of tuberculosis: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Therapeutic effects of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

DNA vaccines: progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Pulmonary necrosis resulting from DNA vaccination against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Therapy of tuberculosis in mice by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

HIV-1 protease has a genetic T-cell adjuvant effect which is negatively regulated by proteolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Antigen selection based on expression levels during infection facilitates vaccine development for an intracellular pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

7 January 2021

Preclinical testing of new vaccines for tuberculosis: a comprehensive review

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

7 January 2021

Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

7 January 2021

The immunogenicity of single and combination DNA vaccines against tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FGT.2011.140

7 January 2021

Identifiers

DOI

10.1038/GT.2011.140

1 reference

17 December 2017

Dimensions Publication ID

1002089501

0 references

1 reference

17 December 2017